Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.57 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.57 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.49 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842846 | 1.00 | CDK5 (0.57) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL28142697 | 0.84 | CDK5 (0.57) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL14883710 | 0.83 | CDK5 (0.68) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL28086697 | 0.83 | NR1I3 (0.68) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL21206237 | 0.83 | CDK5 (0.68) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL16385901 | 0.83 | CDK5 (0.68) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL31315001 | 0.83 | CDK5 (0.56) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL21206146 | 0.83 | CDK5 (0.68) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL16385945 | 0.82 | CDK5 (0.70) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL18845131 | 0.82 | CDK5 (0.70) | CDK5CDK5R1NR1I3GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038050-B2 | Method for the preparation of highly pure 1-androstene derivatives | HANMI PHARM. CO., LTD. (KR) | 2006-05-02 | — | — | US | claimed |
| EP-1646640-A1 | METHOD FOR THE PREPARATION OF HIGHLY PURE 1-ANDROSTENE DERIVATIVES | Hanmi Pharm. Co., Ltd. (KR) | 2006-04-19 | — | — | EP | claimed |
| US-20050245744-A1 | Method for the preparation of highly pure 1-androstene derivatives | HANMI PHARM. CO., LTLD. (KR) | 2005-11-03 | — | — | US | claimed |
| WO-2005007670-A1 | METHOD FOR THE PREPARATION OF HIGHLY PURE 1-ANDROSTENE DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2005-01-27 | — | — | WO | claimed |
| US-7038050-B2 | Method for the preparation of highly pure 1-androstene derivatives | HANMI PHARM. CO., LTD. (KR) | 2006-05-02 | — | — | US | disclosed |
| US-7038050-B2 | Method for the preparation of highly pure 1-androstene derivatives | HANMI PHARM. CO., LTD. (KR) | 2006-05-02 | — | — | US | disclosed |
| EP-1646640-A1 | METHOD FOR THE PREPARATION OF HIGHLY PURE 1-ANDROSTENE DERIVATIVES | Hanmi Pharm. Co., Ltd. (KR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1646640-A1 | METHOD FOR THE PREPARATION OF HIGHLY PURE 1-ANDROSTENE DERIVATIVES | Hanmi Pharm. Co., Ltd. (KR) | 2006-04-19 | — | — | EP | disclosed |
| US-20050245744-A1 | Method for the preparation of highly pure 1-androstene derivatives | HANMI PHARM. CO., LTLD. (KR) | 2005-11-03 | — | — | US | disclosed |
| US-20050245744-A1 | Method for the preparation of highly pure 1-androstene derivatives | HANMI PHARM. CO., LTLD. (KR) | 2005-11-03 | — | — | US | disclosed |
| WO-2005007670-A1 | METHOD FOR THE PREPARATION OF HIGHLY PURE 1-ANDROSTENE DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007670-A1 | METHOD FOR THE PREPARATION OF HIGHLY PURE 1-ANDROSTENE DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245744-A1 | Method for the preparation of highly pure 1-androstene derivatives | CYP19A1, HSD17B11, CYP17A1 | CDK5 1020/4885CDK5R1 595/4885NR1I3 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.